BioSyngen is pioneering T-cell immunotherapies to combat various aggressive cancers. Committed to advancing innovative immune-cell therapy technologies, BioSyngen focuses on the clinical and commercial development of cutting-edge treatments aimed at transforming cancer care and improving patient outcomes.
National Ranking1564th
in Singapore Regional Ranking3195th
in South East Asia Global Ranking91469th
worldwide Rankings by